Hypophosphatasia: Skeletal Abnormalities and Metabolic Bone Disease
Hypophosphatasia (HPP) represents an inherited metabolic bone disease characterized by
defective mineralization of bone and teeth due to low levels of tissue-nonspecific alkaline
phosphatase (TNSALP). The condition arises from loss-of-function variants in the ALPL
gene encoding TNSALP, disrupting bone matrix mineralization through impaired
pyrophosphate hydrolysis. Clinical presentations range from perinatal to adult-onset forms
dependent on residual enzymatic activity and involvement of extraskeletal sites like the liver,
kidney, and lungs.
This review summarizes TNSALP biology regulating skeletal mineralization, the spectrum of
HPP clinical phenotypes linked to ALPL genotype, diagnostic testing through biochemical
and genetic confirmation, and emerging enzyme replacement therapies recently approved
showing efficacy addressing skeletal manifestations and complications. By understanding
how disrupted ALPL signaling impacts skeletal mineralization, continued research promises
further delineating genotype-phenotype correlations and optimizing management alleviating
disease burden through individualized precision approaches.
Physiological Role of TNSALP
TNSALP dephosphorylates inorganic pyrophosphate (PPi), an inhibitor of hydroxyapatite
crystal growth that regulates mineralization:
- Produced by osteoblasts/chrondrocytes, TNSALP anchors cell surfaces through a
glycosylphosphatidylinositol linkage.
- Hydrolyzing PPi favors hydroxyapatite mineral deposition within newly formed bone
osteoid and growth plate cartilage.
- Other substrates include phosphoethanolamine involved in lipid metabolism.
- Ubiquitously expressed, with predominant skeletal localization and liver/kidney
involvement in certain perinatal HPP presentations.
Deficient TNSALP activity elevates PPi, impairing skeletal mineralization through reduced
hydroxyapatite nucleation/crystal growth leading to hypomineralization manifestations across
developmental and aging bones.
Clinical Features of HPP
Presentations depend on residual TNSALP activity levels:
- Perinatal (lethal) - Undermineralized bones, fractures, respiratory failure.
- Perinatal benign - Shortened long bones, fractures, defective teeth.
- Infantile - Wormian bones, craniosynostosis, seizures due to rickets.
- Childhood/adult - Fractures, back pain, premature loss of teeth.
- Odonto - Dental abnormalities involving premature tooth loss.
- Benign - Rare, asymptomatic mild elevations in bone/liver enzymes.
Additional complications like renal calcifications/failure possibly impact liver and heart
valvular function in subset. Phenotypes show intrafamilial variability.
Genetics of HPP
All arise from biallelic loss of function mutations in ALPL encoding the TNSALP
phosphatase:
- Over 300 ALPL variants span missense, nonsense, splicing defects impacting
activity/stability.
- Variable expressivity depends on residual enzymatic activity from mutations conferring
partial versus complete loss of function.
- Homozygosity associated with severe perinatal phenotypes while heterozygosity often
reflects milder adult/odonto presentations.
Molecular diagnosis allows predictive testing, confirming a diagnostic role and guiding
disease management planning for genetic counseling.
Diagnosis
Based upon clinical, radiological and biochemical characteristics:
- Low serum alkaline phosphatase levels confirm through enzymatic assay.
- Increased urinary PPi and Pi ratios evidence impaired hydrolysis.
- Severe hypomineralization observed on plain films/DEXA scanning.
- Genetic testing establishes causality identifying ALPL variants.
A high index of suspicion guides tissue biopsy/enzyme histochemistry or genetic analysis
establishing HPP diagnosis through correlated evidence of deficiency.
Disease Management
Supportive care addresses morbidity utilizing multidisciplinary teams:
- Anticonvulsants manage epilepsy. Anti-rickets vitamin/mineral supplementation.
- Bisphosphonates, parathyroid hormone use show variable efficacy.
- Surgical intervention addresses pseudofractures/craniosynostosis.
- Orthopedic bracing, mobility aids address fractures/deformities.
- Dental care extracts affected teeth, braces retainers for those at risk.
- Enzyme replacement therapies recently approved demonstrate efficacy improving skeletal
health and stabilizing disease course.
- Bone marrow/liver transplant explored but enzymatic supplementation preferred.
- Palliative symptom control addresses bone pain/mobility impairment quality of life.
Future Directions
Research aims improving quality of life through management refinements:
- Clarifying genotype-phenotype relationships guiding prognostication and early intervention
timing.
- Assessment of long-term enzyme replacement therapy outcomes and monitoring.
- Developmental biomarker identification enables newborn screening program
implementation.
- Gene/cellular therapies deliver TNSALP more broadly throughout skeletal tissues.
- Disease modeling explores modifying secondary pathways contributing to
hypomineralization for adjunct targeting.
Overall, continued efforts optimizing HPP recognition and precision care centered on
mechanistic understanding promise mitigating morbidity from this treatable orphan bone
disease.
Hypophosphatasia (HPP) represents an inherited metabolic bone disease characterized by
defective mineralization of bone and teeth due to low levels of tissue-nonspecific alkaline
phosphatase (TNSALP). The condition arises from loss-of-function variants in the ALPL
gene encoding TNSALP, disrupting bone matrix mineralization through impaired
pyrophosphate hydrolysis. Clinical presentations range from perinatal to adult-onset forms
dependent on residual enzymatic activity and involvement of extraskeletal sites like the liver,
kidney, and lungs.
This review summarizes TNSALP biology regulating skeletal mineralization, the spectrum of
HPP clinical phenotypes linked to ALPL genotype, diagnostic testing through biochemical
and genetic confirmation, and emerging enzyme replacement therapies recently approved
showing efficacy addressing skeletal manifestations and complications. By understanding
how disrupted ALPL signaling impacts skeletal mineralization, continued research promises
further delineating genotype-phenotype correlations and optimizing management alleviating
disease burden through individualized precision approaches.
Physiological Role of TNSALP
TNSALP dephosphorylates inorganic pyrophosphate (PPi), an inhibitor of hydroxyapatite
crystal growth that regulates mineralization:
- Produced by osteoblasts/chrondrocytes, TNSALP anchors cell surfaces through a
glycosylphosphatidylinositol linkage.
- Hydrolyzing PPi favors hydroxyapatite mineral deposition within newly formed bone
osteoid and growth plate cartilage.
- Other substrates include phosphoethanolamine involved in lipid metabolism.
- Ubiquitously expressed, with predominant skeletal localization and liver/kidney
involvement in certain perinatal HPP presentations.
Deficient TNSALP activity elevates PPi, impairing skeletal mineralization through reduced
hydroxyapatite nucleation/crystal growth leading to hypomineralization manifestations across
developmental and aging bones.
Clinical Features of HPP
Presentations depend on residual TNSALP activity levels:
- Perinatal (lethal) - Undermineralized bones, fractures, respiratory failure.
- Perinatal benign - Shortened long bones, fractures, defective teeth.
- Infantile - Wormian bones, craniosynostosis, seizures due to rickets.
- Childhood/adult - Fractures, back pain, premature loss of teeth.
- Odonto - Dental abnormalities involving premature tooth loss.
- Benign - Rare, asymptomatic mild elevations in bone/liver enzymes.
Additional complications like renal calcifications/failure possibly impact liver and heart
valvular function in subset. Phenotypes show intrafamilial variability.
Genetics of HPP
All arise from biallelic loss of function mutations in ALPL encoding the TNSALP
phosphatase:
- Over 300 ALPL variants span missense, nonsense, splicing defects impacting
activity/stability.
- Variable expressivity depends on residual enzymatic activity from mutations conferring
partial versus complete loss of function.
- Homozygosity associated with severe perinatal phenotypes while heterozygosity often
reflects milder adult/odonto presentations.
Molecular diagnosis allows predictive testing, confirming a diagnostic role and guiding
disease management planning for genetic counseling.
Diagnosis
Based upon clinical, radiological and biochemical characteristics:
- Low serum alkaline phosphatase levels confirm through enzymatic assay.
- Increased urinary PPi and Pi ratios evidence impaired hydrolysis.
- Severe hypomineralization observed on plain films/DEXA scanning.
- Genetic testing establishes causality identifying ALPL variants.
A high index of suspicion guides tissue biopsy/enzyme histochemistry or genetic analysis
establishing HPP diagnosis through correlated evidence of deficiency.
Disease Management
Supportive care addresses morbidity utilizing multidisciplinary teams:
- Anticonvulsants manage epilepsy. Anti-rickets vitamin/mineral supplementation.
- Bisphosphonates, parathyroid hormone use show variable efficacy.
- Surgical intervention addresses pseudofractures/craniosynostosis.
- Orthopedic bracing, mobility aids address fractures/deformities.
- Dental care extracts affected teeth, braces retainers for those at risk.
- Enzyme replacement therapies recently approved demonstrate efficacy improving skeletal
health and stabilizing disease course.
- Bone marrow/liver transplant explored but enzymatic supplementation preferred.
- Palliative symptom control addresses bone pain/mobility impairment quality of life.
Future Directions
Research aims improving quality of life through management refinements:
- Clarifying genotype-phenotype relationships guiding prognostication and early intervention
timing.
- Assessment of long-term enzyme replacement therapy outcomes and monitoring.
- Developmental biomarker identification enables newborn screening program
implementation.
- Gene/cellular therapies deliver TNSALP more broadly throughout skeletal tissues.
- Disease modeling explores modifying secondary pathways contributing to
hypomineralization for adjunct targeting.
Overall, continued efforts optimizing HPP recognition and precision care centered on
mechanistic understanding promise mitigating morbidity from this treatable orphan bone
disease.
Hypophosphatasia (HPP) represents an inherited metabolic bone disease characterized by
defective mineralization of bone and teeth due to low levels of tissue-nonspecific alkaline
phosphatase (TNSALP). The condition arises from loss-of-function variants in the ALPL
gene encoding TNSALP, disrupting bone matrix mineralization through impaired
pyrophosphate hydrolysis. Clinical presentations range from perinatal to adult-onset forms
dependent on residual enzymatic activity and involvement of extraskeletal sites like the liver,
kidney, and lungs.
This review summarizes TNSALP biology regulating skeletal mineralization, the spectrum of
HPP clinical phenotypes linked to ALPL genotype, diagnostic testing through biochemical
and genetic confirmation, and emerging enzyme replacement therapies recently approved
showing efficacy addressing skeletal manifestations and complications. By understanding
how disrupted ALPL signaling impacts skeletal mineralization, continued research promises
further delineating genotype-phenotype correlations and optimizing management alleviating
disease burden through individualized precision approaches.
Physiological Role of TNSALP
TNSALP dephosphorylates inorganic pyrophosphate (PPi), an inhibitor of hydroxyapatite
crystal growth that regulates mineralization:
- Produced by osteoblasts/chrondrocytes, TNSALP anchors cell surfaces through a
glycosylphosphatidylinositol linkage.
- Hydrolyzing PPi favors hydroxyapatite mineral deposition within newly formed bone
osteoid and growth plate cartilage.
- Other substrates include phosphoethanolamine involved in lipid metabolism.
- Ubiquitously expressed, with predominant skeletal localization and liver/kidney
involvement in certain perinatal HPP presentations.
Deficient TNSALP activity elevates PPi, impairing skeletal mineralization through reduced
hydroxyapatite nucleation/crystal growth leading to hypomineralization manifestations across
developmental and aging bones.
Clinical Features of HPP
Presentations depend on residual TNSALP activity levels:
- Perinatal (lethal) - Undermineralized bones, fractures, respiratory failure.
- Perinatal benign - Shortened long bones, fractures, defective teeth.
- Infantile - Wormian bones, craniosynostosis, seizures due to rickets.
- Childhood/adult - Fractures, back pain, premature loss of teeth.
- Odonto - Dental abnormalities involving premature tooth loss.
- Benign - Rare, asymptomatic mild elevations in bone/liver enzymes.
Additional complications like renal calcifications/failure possibly impact liver and heart
valvular function in subset. Phenotypes show intrafamilial variability.
Genetics of HPP
All arise from biallelic loss of function mutations in ALPL encoding the TNSALP
phosphatase:
- Over 300 ALPL variants span missense, nonsense, splicing defects impacting
activity/stability.
- Variable expressivity depends on residual enzymatic activity from mutations conferring
partial versus complete loss of function.
- Homozygosity associated with severe perinatal phenotypes while heterozygosity often
reflects milder adult/odonto presentations.
Molecular diagnosis allows predictive testing, confirming a diagnostic role and guiding
disease management planning for genetic counseling.
Diagnosis
Based upon clinical, radiological and biochemical characteristics:
- Low serum alkaline phosphatase levels confirm through enzymatic assay.
- Increased urinary PPi and Pi ratios evidence impaired hydrolysis.
- Severe hypomineralization observed on plain films/DEXA scanning.
- Genetic testing establishes causality identifying ALPL variants.
A high index of suspicion guides tissue biopsy/enzyme histochemistry or genetic analysis
establishing HPP diagnosis through correlated evidence of deficiency.
Disease Management
Supportive care addresses morbidity utilizing multidisciplinary teams:
- Anticonvulsants manage epilepsy. Anti-rickets vitamin/mineral supplementation.
- Bisphosphonates, parathyroid hormone use show variable efficacy.
- Surgical intervention addresses pseudofractures/craniosynostosis.
- Orthopedic bracing, mobility aids address fractures/deformities.
- Dental care extracts affected teeth, braces retainers for those at risk.
- Enzyme replacement therapies recently approved demonstrate efficacy improving skeletal
health and stabilizing disease course.
- Bone marrow/liver transplant explored but enzymatic supplementation preferred.
- Palliative symptom control addresses bone pain/mobility impairment quality of life.
Future Directions
Research aims improving quality of life through management refinements:
- Clarifying genotype-phenotype relationships guiding prognostication and early intervention
timing.
- Assessment of long-term enzyme replacement therapy outcomes and monitoring.
- Developmental biomarker identification enables newborn screening program
implementation.
- Gene/cellular therapies deliver TNSALP more broadly throughout skeletal tissues.
- Disease modeling explores modifying secondary pathways contributing to
hypomineralization for adjunct targeting.
Overall, continued efforts optimizing HPP recognition and precision care centered on
mechanistic understanding promise mitigating morbidity from this treatable orphan bone
disease.
Hypophosphatasia (HPP) represents an inherited metabolic bone disease characterized by
defective mineralization of bone and teeth due to low levels of tissue-nonspecific alkaline
phosphatase (TNSALP). The condition arises from loss-of-function variants in the ALPL
gene encoding TNSALP, disrupting bone matrix mineralization through impaired
pyrophosphate hydrolysis. Clinical presentations range from perinatal to adult-onset forms
dependent on residual enzymatic activity and involvement of extraskeletal sites like the liver,
kidney, and lungs.
This review summarizes TNSALP biology regulating skeletal mineralization, the spectrum of
HPP clinical phenotypes linked to ALPL genotype, diagnostic testing through biochemical
and genetic confirmation, and emerging enzyme replacement therapies recently approved
showing efficacy addressing skeletal manifestations and complications. By understanding
how disrupted ALPL signaling impacts skeletal mineralization, continued research promises
further delineating genotype-phenotype correlations and optimizing management alleviating
disease burden through individualized precision approaches.
Physiological Role of TNSALP
TNSALP dephosphorylates inorganic pyrophosphate (PPi), an inhibitor of hydroxyapatite
crystal growth that regulates mineralization:
- Produced by osteoblasts/chrondrocytes, TNSALP anchors cell surfaces through a
glycosylphosphatidylinositol linkage.
- Hydrolyzing PPi favors hydroxyapatite mineral deposition within newly formed bone
osteoid and growth plate cartilage.
- Other substrates include phosphoethanolamine involved in lipid metabolism.
- Ubiquitously expressed, with predominant skeletal localization and liver/kidney
involvement in certain perinatal HPP presentations.
Deficient TNSALP activity elevates PPi, impairing skeletal mineralization through reduced
hydroxyapatite nucleation/crystal growth leading to hypomineralization manifestations across
developmental and aging bones.
Clinical Features of HPP
Presentations depend on residual TNSALP activity levels:
- Perinatal (lethal) - Undermineralized bones, fractures, respiratory failure.
- Perinatal benign - Shortened long bones, fractures, defective teeth.
- Infantile - Wormian bones, craniosynostosis, seizures due to rickets.
- Childhood/adult - Fractures, back pain, premature loss of teeth.
- Odonto - Dental abnormalities involving premature tooth loss.
- Benign - Rare, asymptomatic mild elevations in bone/liver enzymes.
Additional complications like renal calcifications/failure possibly impact liver and heart
valvular function in subset. Phenotypes show intrafamilial variability.
Genetics of HPP
All arise from biallelic loss of function mutations in ALPL encoding the TNSALP
phosphatase:
- Over 300 ALPL variants span missense, nonsense, splicing defects impacting
activity/stability.
- Variable expressivity depends on residual enzymatic activity from mutations conferring
partial versus complete loss of function.
- Homozygosity associated with severe perinatal phenotypes while heterozygosity often
reflects milder adult/odonto presentations.
Molecular diagnosis allows predictive testing, confirming a diagnostic role and guiding
disease management planning for genetic counseling.
Diagnosis
Based upon clinical, radiological and biochemical characteristics:
- Low serum alkaline phosphatase levels confirm through enzymatic assay.
- Increased urinary PPi and Pi ratios evidence impaired hydrolysis.
- Severe hypomineralization observed on plain films/DEXA scanning.
- Genetic testing establishes causality identifying ALPL variants.
A high index of suspicion guides tissue biopsy/enzyme histochemistry or genetic analysis
establishing HPP diagnosis through correlated evidence of deficiency.
Disease Management
Supportive care addresses morbidity utilizing multidisciplinary teams:
- Anticonvulsants manage epilepsy. Anti-rickets vitamin/mineral supplementation.
- Bisphosphonates, parathyroid hormone use show variable efficacy.
- Surgical intervention addresses pseudofractures/craniosynostosis.
- Orthopedic bracing, mobility aids address fractures/deformities.
- Dental care extracts affected teeth, braces retainers for those at risk.
- Enzyme replacement therapies recently approved demonstrate efficacy improving skeletal
health and stabilizing disease course.
- Bone marrow/liver transplant explored but enzymatic supplementation preferred.
- Palliative symptom control addresses bone pain/mobility impairment quality of life.
Future Directions
Research aims improving quality of life through management refinements:
- Clarifying genotype-phenotype relationships guiding prognostication and early intervention
timing.
- Assessment of long-term enzyme replacement therapy outcomes and monitoring.
- Developmental biomarker identification enables newborn screening program
implementation.
- Gene/cellular therapies deliver TNSALP more broadly throughout skeletal tissues.
- Disease modeling explores modifying secondary pathways contributing to
hypomineralization for adjunct targeting.
Overall, continued efforts optimizing HPP recognition and precision care centered on
mechanistic understanding promise mitigating morbidity from this treatable orphan bone
disease.
Hypophosphatasia (HPP) represents an inherited metabolic bone disease characterized by
defective mineralization of bone and teeth due to low levels of tissue-nonspecific alkaline
phosphatase (TNSALP). The condition arises from loss-of-function variants in the ALPL
gene encoding TNSALP, disrupting bone matrix mineralization through impaired
pyrophosphate hydrolysis. Clinical presentations range from perinatal to adult-onset forms
dependent on residual enzymatic activity and involvement of extraskeletal sites like the liver,
kidney, and lungs.
This review summarizes TNSALP biology regulating skeletal mineralization, the spectrum of
HPP clinical phenotypes linked to ALPL genotype, diagnostic testing through biochemical
and genetic confirmation, and emerging enzyme replacement therapies recently approved
showing efficacy addressing skeletal manifestations and complications. By understanding
how disrupted ALPL signaling impacts skeletal mineralization, continued research promises
further delineating genotype-phenotype correlations and optimizing management alleviating
disease burden through individualized precision approaches.
Physiological Role of TNSALP
TNSALP dephosphorylates inorganic pyrophosphate (PPi), an inhibitor of hydroxyapatite
crystal growth that regulates mineralization:
- Produced by osteoblasts/chrondrocytes, TNSALP anchors cell surfaces through a
glycosylphosphatidylinositol linkage.
- Hydrolyzing PPi favors hydroxyapatite mineral deposition within newly formed bone
osteoid and growth plate cartilage.
- Other substrates include phosphoethanolamine involved in lipid metabolism.
- Ubiquitously expressed, with predominant skeletal localization and liver/kidney
involvement in certain perinatal HPP presentations.
Deficient TNSALP activity elevates PPi, impairing skeletal mineralization through reduced
hydroxyapatite nucleation/crystal growth leading to hypomineralization manifestations across
developmental and aging bones.
Clinical Features of HPP
Presentations depend on residual TNSALP activity levels:
- Perinatal (lethal) - Undermineralized bones, fractures, respiratory failure.
- Perinatal benign - Shortened long bones, fractures, defective teeth.
- Infantile - Wormian bones, craniosynostosis, seizures due to rickets.
- Childhood/adult - Fractures, back pain, premature loss of teeth.
- Odonto - Dental abnormalities involving premature tooth loss.
- Benign - Rare, asymptomatic mild elevations in bone/liver enzymes.
Additional complications like renal calcifications/failure possibly impact liver and heart
valvular function in subset. Phenotypes show intrafamilial variability.
Genetics of HPP
All arise from biallelic loss of function mutations in ALPL encoding the TNSALP
phosphatase:
- Over 300 ALPL variants span missense, nonsense, splicing defects impacting
activity/stability.
- Variable expressivity depends on residual enzymatic activity from mutations conferring
partial versus complete loss of function.
- Homozygosity associated with severe perinatal phenotypes while heterozygosity often
reflects milder adult/odonto presentations.
Molecular diagnosis allows predictive testing, confirming a diagnostic role and guiding
disease management planning for genetic counseling.
Diagnosis
Based upon clinical, radiological and biochemical characteristics:
- Low serum alkaline phosphatase levels confirm through enzymatic assay.
- Increased urinary PPi and Pi ratios evidence impaired hydrolysis.
- Severe hypomineralization observed on plain films/DEXA scanning.
- Genetic testing establishes causality identifying ALPL variants.
A high index of suspicion guides tissue biopsy/enzyme histochemistry or genetic analysis
establishing HPP diagnosis through correlated evidence of deficiency.
Disease Management
Supportive care addresses morbidity utilizing multidisciplinary teams:
- Anticonvulsants manage epilepsy. Anti-rickets vitamin/mineral supplementation.
- Bisphosphonates, parathyroid hormone use show variable efficacy.
- Surgical intervention addresses pseudofractures/craniosynostosis.
- Orthopedic bracing, mobility aids address fractures/deformities.
- Dental care extracts affected teeth, braces retainers for those at risk.
- Enzyme replacement therapies recently approved demonstrate efficacy improving skeletal
health and stabilizing disease course.
- Bone marrow/liver transplant explored but enzymatic supplementation preferred.
- Palliative symptom control addresses bone pain/mobility impairment quality of life.
Future Directions
Research aims improving quality of life through management refinements:
- Clarifying genotype-phenotype relationships guiding prognostication and early intervention
timing.
- Assessment of long-term enzyme replacement therapy outcomes and monitoring.
- Developmental biomarker identification enables newborn screening program
implementation.
- Gene/cellular therapies deliver TNSALP more broadly throughout skeletal tissues.
- Disease modeling explores modifying secondary pathways contributing to
hypomineralization for adjunct targeting.
Overall, continued efforts optimizing HPP recognition and precision care centered on
mechanistic understanding promise mitigating morbidity from this treatable orphan bone
disease.
Hypophosphatasia (HPP) represents an inherited metabolic bone disease characterized by
defective mineralization of bone and teeth due to low levels of tissue-nonspecific alkaline
phosphatase (TNSALP). The condition arises from loss-of-function variants in the ALPL
gene encoding TNSALP, disrupting bone matrix mineralization through impaired
pyrophosphate hydrolysis. Clinical presentations range from perinatal to adult-onset forms
dependent on residual enzymatic activity and involvement of extraskeletal sites like the liver,
kidney, and lungs.
This review summarizes TNSALP biology regulating skeletal mineralization, the spectrum of
HPP clinical phenotypes linked to ALPL genotype, diagnostic testing through biochemical
and genetic confirmation, and emerging enzyme replacement therapies recently approved
showing efficacy addressing skeletal manifestations and complications. By understanding
how disrupted ALPL signaling impacts skeletal mineralization, continued research promises
further delineating genotype-phenotype correlations and optimizing management alleviating
disease burden through individualized precision approaches.
Physiological Role of TNSALP
TNSALP dephosphorylates inorganic pyrophosphate (PPi), an inhibitor of hydroxyapatite
crystal growth that regulates mineralization:
- Produced by osteoblasts/chrondrocytes, TNSALP anchors cell surfaces through a
glycosylphosphatidylinositol linkage.
- Hydrolyzing PPi favors hydroxyapatite mineral deposition within newly formed bone
osteoid and growth plate cartilage.
- Other substrates include phosphoethanolamine involved in lipid metabolism.
- Ubiquitously expressed, with predominant skeletal localization and liver/kidney
involvement in certain perinatal HPP presentations.
Deficient TNSALP activity elevates PPi, impairing skeletal mineralization through reduced
hydroxyapatite nucleation/crystal growth leading to hypomineralization manifestations across
developmental and aging bones.
Clinical Features of HPP
Presentations depend on residual TNSALP activity levels:
- Perinatal (lethal) - Undermineralized bones, fractures, respiratory failure.
- Perinatal benign - Shortened long bones, fractures, defective teeth.
- Infantile - Wormian bones, craniosynostosis, seizures due to rickets.
- Childhood/adult - Fractures, back pain, premature loss of teeth.
- Odonto - Dental abnormalities involving premature tooth loss.
- Benign - Rare, asymptomatic mild elevations in bone/liver enzymes.
Additional complications like renal calcifications/failure possibly impact liver and heart
valvular function in subset. Phenotypes show intrafamilial variability.
Genetics of HPP
All arise from biallelic loss of function mutations in ALPL encoding the TNSALP
phosphatase:
- Over 300 ALPL variants span missense, nonsense, splicing defects impacting
activity/stability.
- Variable expressivity depends on residual enzymatic activity from mutations conferring
partial versus complete loss of function.
- Homozygosity associated with severe perinatal phenotypes while heterozygosity often
reflects milder adult/odonto presentations.
Molecular diagnosis allows predictive testing, confirming a diagnostic role and guiding
disease management planning for genetic counseling.
Diagnosis
Based upon clinical, radiological and biochemical characteristics:
- Low serum alkaline phosphatase levels confirm through enzymatic assay.
- Increased urinary PPi and Pi ratios evidence impaired hydrolysis.
- Severe hypomineralization observed on plain films/DEXA scanning.
- Genetic testing establishes causality identifying ALPL variants.
A high index of suspicion guides tissue biopsy/enzyme histochemistry or genetic analysis
establishing HPP diagnosis through correlated evidence of deficiency.
Disease Management
Supportive care addresses morbidity utilizing multidisciplinary teams:
- Anticonvulsants manage epilepsy. Anti-rickets vitamin/mineral supplementation.
- Bisphosphonates, parathyroid hormone use show variable efficacy.
- Surgical intervention addresses pseudofractures/craniosynostosis.
- Orthopedic bracing, mobility aids address fractures/deformities.
- Dental care extracts affected teeth, braces retainers for those at risk.
- Enzyme replacement therapies recently approved demonstrate efficacy improving skeletal
health and stabilizing disease course.
- Bone marrow/liver transplant explored but enzymatic supplementation preferred.
- Palliative symptom control addresses bone pain/mobility impairment quality of life.
Future Directions
Research aims improving quality of life through management refinements:
- Clarifying genotype-phenotype relationships guiding prognostication and early intervention
timing.
- Assessment of long-term enzyme replacement therapy outcomes and monitoring.
- Developmental biomarker identification enables newborn screening program
implementation.
- Gene/cellular therapies deliver TNSALP more broadly throughout skeletal tissues.
- Disease modeling explores modifying secondary pathways contributing to
hypomineralization for adjunct targeting.
Overall, continued efforts optimizing HPP recognition and precision care centered on
mechanistic understanding promise mitigating morbidity from this treatable orphan bone
disease.
Hypophosphatasia (HPP) represents an inherited metabolic bone disease characterized by
defective mineralization of bone and teeth due to low levels of tissue-nonspecific alkaline
phosphatase (TNSALP). The condition arises from loss-of-function variants in the ALPL
gene encoding TNSALP, disrupting bone matrix mineralization through impaired
pyrophosphate hydrolysis. Clinical presentations range from perinatal to adult-onset forms
dependent on residual enzymatic activity and involvement of extraskeletal sites like the liver,
kidney, and lungs.
This review summarizes TNSALP biology regulating skeletal mineralization, the spectrum of
HPP clinical phenotypes linked to ALPL genotype, diagnostic testing through biochemical
and genetic confirmation, and emerging enzyme replacement therapies recently approved
showing efficacy addressing skeletal manifestations and complications. By understanding
how disrupted ALPL signaling impacts skeletal mineralization, continued research promises
further delineating genotype-phenotype correlations and optimizing management alleviating
disease burden through individualized precision approaches.
Physiological Role of TNSALP
TNSALP dephosphorylates inorganic pyrophosphate (PPi), an inhibitor of hydroxyapatite
crystal growth that regulates mineralization:
- Produced by osteoblasts/chrondrocytes, TNSALP anchors cell surfaces through a
glycosylphosphatidylinositol linkage.
- Hydrolyzing PPi favors hydroxyapatite mineral deposition within newly formed bone
osteoid and growth plate cartilage.
- Other substrates include phosphoethanolamine involved in lipid metabolism.
- Ubiquitously expressed, with predominant skeletal localization and liver/kidney
involvement in certain perinatal HPP presentations.
Deficient TNSALP activity elevates PPi, impairing skeletal mineralization through reduced
hydroxyapatite nucleation/crystal growth leading to hypomineralization manifestations across
developmental and aging bones.
Clinical Features of HPP
Presentations depend on residual TNSALP activity levels:
- Perinatal (lethal) - Undermineralized bones, fractures, respiratory failure.
- Perinatal benign - Shortened long bones, fractures, defective teeth.
- Infantile - Wormian bones, craniosynostosis, seizures due to rickets.
- Childhood/adult - Fractures, back pain, premature loss of teeth.
- Odonto - Dental abnormalities involving premature tooth loss.
- Benign - Rare, asymptomatic mild elevations in bone/liver enzymes.
Additional complications like renal calcifications/failure possibly impact liver and heart
valvular function in subset. Phenotypes show intrafamilial variability.
Genetics of HPP
All arise from biallelic loss of function mutations in ALPL encoding the TNSALP
phosphatase:
- Over 300 ALPL variants span missense, nonsense, splicing defects impacting
activity/stability.
- Variable expressivity depends on residual enzymatic activity from mutations conferring
partial versus complete loss of function.
- Homozygosity associated with severe perinatal phenotypes while heterozygosity often
reflects milder adult/odonto presentations.
Molecular diagnosis allows predictive testing, confirming a diagnostic role and guiding
disease management planning for genetic counseling.
Diagnosis
Based upon clinical, radiological and biochemical characteristics:
- Low serum alkaline phosphatase levels confirm through enzymatic assay.
- Increased urinary PPi and Pi ratios evidence impaired hydrolysis.
- Severe hypomineralization observed on plain films/DEXA scanning.
- Genetic testing establishes causality identifying ALPL variants.
A high index of suspicion guides tissue biopsy/enzyme histochemistry or genetic analysis
establishing HPP diagnosis through correlated evidence of deficiency.
Disease Management
Supportive care addresses morbidity utilizing multidisciplinary teams:
- Anticonvulsants manage epilepsy. Anti-rickets vitamin/mineral supplementation.
- Bisphosphonates, parathyroid hormone use show variable efficacy.
- Surgical intervention addresses pseudofractures/craniosynostosis.
- Orthopedic bracing, mobility aids address fractures/deformities.
- Dental care extracts affected teeth, braces retainers for those at risk.
- Enzyme replacement therapies recently approved demonstrate efficacy improving skeletal
health and stabilizing disease course.
- Bone marrow/liver transplant explored but enzymatic supplementation preferred.
- Palliative symptom control addresses bone pain/mobility impairment quality of life.
Future Directions
Research aims improving quality of life through management refinements:
- Clarifying genotype-phenotype relationships guiding prognostication and early intervention
timing.
- Assessment of long-term enzyme replacement therapy outcomes and monitoring.
- Developmental biomarker identification enables newborn screening program
implementation.
- Gene/cellular therapies deliver TNSALP more broadly throughout skeletal tissues.
- Disease modeling explores modifying secondary pathways contributing to
hypomineralization for adjunct targeting.
Overall, continued efforts optimizing HPP recognition and precision care centered on
mechanistic understanding promise mitigating morbidity from this treatable orphan bone
disease.
Hypophosphatasia (HPP) represents an inherited metabolic bone disease characterized by
defective mineralization of bone and teeth due to low levels of tissue-nonspecific alkaline
phosphatase (TNSALP). The condition arises from loss-of-function variants in the ALPL
gene encoding TNSALP, disrupting bone matrix mineralization through impaired
pyrophosphate hydrolysis. Clinical presentations range from perinatal to adult-onset forms
dependent on residual enzymatic activity and involvement of extraskeletal sites like the liver,
kidney, and lungs.
This review summarizes TNSALP biology regulating skeletal mineralization, the spectrum of
HPP clinical phenotypes linked to ALPL genotype, diagnostic testing through biochemical
and genetic confirmation, and emerging enzyme replacement therapies recently approved
showing efficacy addressing skeletal manifestations and complications. By understanding
how disrupted ALPL signaling impacts skeletal mineralization, continued research promises
further delineating genotype-phenotype correlations and optimizing management alleviating
disease burden through individualized precision approaches.
Physiological Role of TNSALP
TNSALP dephosphorylates inorganic pyrophosphate (PPi), an inhibitor of hydroxyapatite
crystal growth that regulates mineralization:
- Produced by osteoblasts/chrondrocytes, TNSALP anchors cell surfaces through a
glycosylphosphatidylinositol linkage.
- Hydrolyzing PPi favors hydroxyapatite mineral deposition within newly formed bone
osteoid and growth plate cartilage.
- Other substrates include phosphoethanolamine involved in lipid metabolism.
- Ubiquitously expressed, with predominant skeletal localization and liver/kidney
involvement in certain perinatal HPP presentations.
Deficient TNSALP activity elevates PPi, impairing skeletal mineralization through reduced
hydroxyapatite nucleation/crystal growth leading to hypomineralization manifestations across
developmental and aging bones.
Clinical Features of HPP
Presentations depend on residual TNSALP activity levels:
- Perinatal (lethal) - Undermineralized bones, fractures, respiratory failure.
- Perinatal benign - Shortened long bones, fractures, defective teeth.
- Infantile - Wormian bones, craniosynostosis, seizures due to rickets.
- Childhood/adult - Fractures, back pain, premature loss of teeth.
- Odonto - Dental abnormalities involving premature tooth loss.
- Benign - Rare, asymptomatic mild elevations in bone/liver enzymes.
Additional complications like renal calcifications/failure possibly impact liver and heart
valvular function in subset. Phenotypes show intrafamilial variability.
Genetics of HPP
All arise from biallelic loss of function mutations in ALPL encoding the TNSALP
phosphatase:
- Over 300 ALPL variants span missense, nonsense, splicing defects impacting
activity/stability.
- Variable expressivity depends on residual enzymatic activity from mutations conferring
partial versus complete loss of function.
- Homozygosity associated with severe perinatal phenotypes while heterozygosity often
reflects milder adult/odonto presentations.
Molecular diagnosis allows predictive testing, confirming a diagnostic role and guiding
disease management planning for genetic counseling.
Diagnosis
Based upon clinical, radiological and biochemical characteristics:
- Low serum alkaline phosphatase levels confirm through enzymatic assay.
- Increased urinary PPi and Pi ratios evidence impaired hydrolysis.
- Severe hypomineralization observed on plain films/DEXA scanning.
- Genetic testing establishes causality identifying ALPL variants.
A high index of suspicion guides tissue biopsy/enzyme histochemistry or genetic analysis
establishing HPP diagnosis through correlated evidence of deficiency.
Disease Management
Supportive care addresses morbidity utilizing multidisciplinary teams:
- Anticonvulsants manage epilepsy. Anti-rickets vitamin/mineral supplementation.
- Bisphosphonates, parathyroid hormone use show variable efficacy.
- Surgical intervention addresses pseudofractures/craniosynostosis.
- Orthopedic bracing, mobility aids address fractures/deformities.
- Dental care extracts affected teeth, braces retainers for those at risk.
- Enzyme replacement therapies recently approved demonstrate efficacy improving skeletal
health and stabilizing disease course.
- Bone marrow/liver transplant explored but enzymatic supplementation preferred.
- Palliative symptom control addresses bone pain/mobility impairment quality of life.
Future Directions
Research aims improving quality of life through management refinements:
- Clarifying genotype-phenotype relationships guiding prognostication and early intervention
timing.
- Assessment of long-term enzyme replacement therapy outcomes and monitoring.
- Developmental biomarker identification enables newborn screening program
implementation.
- Gene/cellular therapies deliver TNSALP more broadly throughout skeletal tissues.
- Disease modeling explores modifying secondary pathways contributing to
hypomineralization for adjunct targeting.
Overall, continued efforts optimizing HPP recognition and precision care centered on
mechanistic understanding promise mitigating morbidity from this treatable orphan bone
disease.
Hypophosphatasia (HPP) represents an inherited metabolic bone disease characterized by
defective mineralization of bone and teeth due to low levels of tissue-nonspecific alkaline
phosphatase (TNSALP). The condition arises from loss-of-function variants in the ALPL
gene encoding TNSALP, disrupting bone matrix mineralization through impaired
pyrophosphate hydrolysis. Clinical presentations range from perinatal to adult-onset forms
dependent on residual enzymatic activity and involvement of extraskeletal sites like the liver,
kidney, and lungs.
This review summarizes TNSALP biology regulating skeletal mineralization, the spectrum of
HPP clinical phenotypes linked to ALPL genotype, diagnostic testing through biochemical
and genetic confirmation, and emerging enzyme replacement therapies recently approved
showing efficacy addressing skeletal manifestations and complications. By understanding
how disrupted ALPL signaling impacts skeletal mineralization, continued research promises
further delineating genotype-phenotype correlations and optimizing management alleviating
disease burden through individualized precision approaches.
Physiological Role of TNSALP
TNSALP dephosphorylates inorganic pyrophosphate (PPi), an inhibitor of hydroxyapatite
crystal growth that regulates mineralization:
- Produced by osteoblasts/chrondrocytes, TNSALP anchors cell surfaces through a
glycosylphosphatidylinositol linkage.
- Hydrolyzing PPi favors hydroxyapatite mineral deposition within newly formed bone
osteoid and growth plate cartilage.
- Other substrates include phosphoethanolamine involved in lipid metabolism.
- Ubiquitously expressed, with predominant skeletal localization and liver/kidney
involvement in certain perinatal HPP presentations.
Deficient TNSALP activity elevates PPi, impairing skeletal mineralization through reduced
hydroxyapatite nucleation/crystal growth leading to hypomineralization manifestations across
developmental and aging bones.
Clinical Features of HPP
Presentations depend on residual TNSALP activity levels:
- Perinatal (lethal) - Undermineralized bones, fractures, respiratory failure.
- Perinatal benign - Shortened long bones, fractures, defective teeth.
- Infantile - Wormian bones, craniosynostosis, seizures due to rickets.
- Childhood/adult - Fractures, back pain, premature loss of teeth.
- Odonto - Dental abnormalities involving premature tooth loss.
- Benign - Rare, asymptomatic mild elevations in bone/liver enzymes.
Additional complications like renal calcifications/failure possibly impact liver and heart
valvular function in subset. Phenotypes show intrafamilial variability.
Genetics of HPP
All arise from biallelic loss of function mutations in ALPL encoding the TNSALP
phosphatase:
- Over 300 ALPL variants span missense, nonsense, splicing defects impacting
activity/stability.
- Variable expressivity depends on residual enzymatic activity from mutations conferring
partial versus complete loss of function.
- Homozygosity associated with severe perinatal phenotypes while heterozygosity often
reflects milder adult/odonto presentations.
Molecular diagnosis allows predictive testing, confirming a diagnostic role and guiding
disease management planning for genetic counseling.
Diagnosis
Based upon clinical, radiological and biochemical characteristics:
- Low serum alkaline phosphatase levels confirm through enzymatic assay.
- Increased urinary PPi and Pi ratios evidence impaired hydrolysis.
- Severe hypomineralization observed on plain films/DEXA scanning.
- Genetic testing establishes causality identifying ALPL variants.
A high index of suspicion guides tissue biopsy/enzyme histochemistry or genetic analysis
establishing HPP diagnosis through correlated evidence of deficiency.
Disease Management
Supportive care addresses morbidity utilizing multidisciplinary teams:
- Anticonvulsants manage epilepsy. Anti-rickets vitamin/mineral supplementation.
- Bisphosphonates, parathyroid hormone use show variable efficacy.
- Surgical intervention addresses pseudofractures/craniosynostosis.
- Orthopedic bracing, mobility aids address fractures/deformities.
- Dental care extracts affected teeth, braces retainers for those at risk.
- Enzyme replacement therapies recently approved demonstrate efficacy improving skeletal
health and stabilizing disease course.
- Bone marrow/liver transplant explored but enzymatic supplementation preferred.
- Palliative symptom control addresses bone pain/mobility impairment quality of life.
Future Directions
Research aims improving quality of life through management refinements:
- Clarifying genotype-phenotype relationships guiding prognostication and early intervention
timing.
- Assessment of long-term enzyme replacement therapy outcomes and monitoring.
- Developmental biomarker identification enables newborn screening program
implementation.
- Gene/cellular therapies deliver TNSALP more broadly throughout skeletal tissues.
- Disease modeling explores modifying secondary pathways contributing to
hypomineralization for adjunct targeting.
Overall, continued efforts optimizing HPP recognition and precision care centered on
mechanistic understanding promise mitigating morbidity from this treatable orphan bone
disease.
Hypophosphatasia (HPP) represents an inherited metabolic bone disease characterized by
defective mineralization of bone and teeth due to low levels of tissue-nonspecific alkaline
phosphatase (TNSALP). The condition arises from loss-of-function variants in the ALPL
gene encoding TNSALP, disrupting bone matrix mineralization through impaired
pyrophosphate hydrolysis. Clinical presentations range from perinatal to adult-onset forms
dependent on residual enzymatic activity and involvement of extraskeletal sites like the liver,
kidney, and lungs.
This review summarizes TNSALP biology regulating skeletal mineralization, the spectrum of
HPP clinical phenotypes linked to ALPL genotype, diagnostic testing through biochemical
and genetic confirmation, and emerging enzyme replacement therapies recently approved
showing efficacy addressing skeletal manifestations and complications. By understanding
how disrupted ALPL signaling impacts skeletal mineralization, continued research promises
further delineating genotype-phenotype correlations and optimizing management alleviating
disease burden through individualized precision approaches.
Physiological Role of TNSALP
TNSALP dephosphorylates inorganic pyrophosphate (PPi), an inhibitor of hydroxyapatite
crystal growth that regulates mineralization:
- Produced by osteoblasts/chrondrocytes, TNSALP anchors cell surfaces through a
glycosylphosphatidylinositol linkage.
- Hydrolyzing PPi favors hydroxyapatite mineral deposition within newly formed bone
osteoid and growth plate cartilage.
- Other substrates include phosphoethanolamine involved in lipid metabolism.
- Ubiquitously expressed, with predominant skeletal localization and liver/kidney
involvement in certain perinatal HPP presentations.
Deficient TNSALP activity elevates PPi, impairing skeletal mineralization through reduced
hydroxyapatite nucleation/crystal growth leading to hypomineralization manifestations across
developmental and aging bones.
Clinical Features of HPP
Presentations depend on residual TNSALP activity levels:
- Perinatal (lethal) - Undermineralized bones, fractures, respiratory failure.
- Perinatal benign - Shortened long bones, fractures, defective teeth.
- Infantile - Wormian bones, craniosynostosis, seizures due to rickets.
- Childhood/adult - Fractures, back pain, premature loss of teeth.
- Odonto - Dental abnormalities involving premature tooth loss.
- Benign - Rare, asymptomatic mild elevations in bone/liver enzymes.
Additional complications like renal calcifications/failure possibly impact liver and heart
valvular function in subset. Phenotypes show intrafamilial variability.
Genetics of HPP
All arise from biallelic loss of function mutations in ALPL encoding the TNSALP
phosphatase:
- Over 300 ALPL variants span missense, nonsense, splicing defects impacting
activity/stability.
- Variable expressivity depends on residual enzymatic activity from mutations conferring
partial versus complete loss of function.
- Homozygosity associated with severe perinatal phenotypes while heterozygosity often
reflects milder adult/odonto presentations.
Molecular diagnosis allows predictive testing, confirming a diagnostic role and guiding
disease management planning for genetic counseling.
Diagnosis
Based upon clinical, radiological and biochemical characteristics:
- Low serum alkaline phosphatase levels confirm through enzymatic assay.
- Increased urinary PPi and Pi ratios evidence impaired hydrolysis.
- Severe hypomineralization observed on plain films/DEXA scanning.
- Genetic testing establishes causality identifying ALPL variants.
A high index of suspicion guides tissue biopsy/enzyme histochemistry or genetic analysis
establishing HPP diagnosis through correlated evidence of deficiency.
Disease Management
Supportive care addresses morbidity utilizing multidisciplinary teams:
- Anticonvulsants manage epilepsy. Anti-rickets vitamin/mineral supplementation.
- Bisphosphonates, parathyroid hormone use show variable efficacy.
- Surgical intervention addresses pseudofractures/craniosynostosis.
- Orthopedic bracing, mobility aids address fractures/deformities.
- Dental care extracts affected teeth, braces retainers for those at risk.
- Enzyme replacement therapies recently approved demonstrate efficacy improving skeletal
health and stabilizing disease course.
- Bone marrow/liver transplant explored but enzymatic supplementation preferred.
- Palliative symptom control addresses bone pain/mobility impairment quality of life.
Future Directions
Research aims improving quality of life through management refinements:
- Clarifying genotype-phenotype relationships guiding prognostication and early intervention
timing.
- Assessment of long-term enzyme replacement therapy outcomes and monitoring.
- Developmental biomarker identification enables newborn screening program
implementation.
- Gene/cellular therapies deliver TNSALP more broadly throughout skeletal tissues.
- Disease modeling explores modifying secondary pathways contributing to
hypomineralization for adjunct targeting.
Overall, continued efforts optimizing HPP recognition and precision care centered on
mechanistic understanding promise mitigating morbidity from this treatable orphan bone
disease.
Hypophosphatasia (HPP) represents an inherited metabolic bone disease characterized by
defective mineralization of bone and teeth due to low levels of tissue-nonspecific alkaline
phosphatase (TNSALP). The condition arises from loss-of-function variants in the ALPL
gene encoding TNSALP, disrupting bone matrix mineralization through impaired
pyrophosphate hydrolysis. Clinical presentations range from perinatal to adult-onset forms
dependent on residual enzymatic activity and involvement of extraskeletal sites like the liver,
kidney, and lungs.
This review summarizes TNSALP biology regulating skeletal mineralization, the spectrum of
HPP clinical phenotypes linked to ALPL genotype, diagnostic testing through biochemical
and genetic confirmation, and emerging enzyme replacement therapies recently approved
showing efficacy addressing skeletal manifestations and complications. By understanding
how disrupted ALPL signaling impacts skeletal mineralization, continued research promises
further delineating genotype-phenotype correlations and optimizing management alleviating
disease burden through individualized precision approaches.
Physiological Role of TNSALP
TNSALP dephosphorylates inorganic pyrophosphate (PPi), an inhibitor of hydroxyapatite
crystal growth that regulates mineralization:
- Produced by osteoblasts/chrondrocytes, TNSALP anchors cell surfaces through a
glycosylphosphatidylinositol linkage.
- Hydrolyzing PPi favors hydroxyapatite mineral deposition within newly formed bone
osteoid and growth plate cartilage.
- Other substrates include phosphoethanolamine involved in lipid metabolism.
- Ubiquitously expressed, with predominant skeletal localization and liver/kidney
involvement in certain perinatal HPP presentations.
Deficient TNSALP activity elevates PPi, impairing skeletal mineralization through reduced
hydroxyapatite nucleation/crystal growth leading to hypomineralization manifestations across
developmental and aging bones.
Clinical Features of HPP
Presentations depend on residual TNSALP activity levels:
- Perinatal (lethal) - Undermineralized bones, fractures, respiratory failure.
- Perinatal benign - Shortened long bones, fractures, defective teeth.
- Infantile - Wormian bones, craniosynostosis, seizures due to rickets.
- Childhood/adult - Fractures, back pain, premature loss of teeth.
- Odonto - Dental abnormalities involving premature tooth loss.
- Benign - Rare, asymptomatic mild elevations in bone/liver enzymes.
Additional complications like renal calcifications/failure possibly impact liver and heart
valvular function in subset. Phenotypes show intrafamilial variability.
Genetics of HPP
All arise from biallelic loss of function mutations in ALPL encoding the TNSALP
phosphatase:
- Over 300 ALPL variants span missense, nonsense, splicing defects impacting
activity/stability.
- Variable expressivity depends on residual enzymatic activity from mutations conferring
partial versus complete loss of function.
- Homozygosity associated with severe perinatal phenotypes while heterozygosity often
reflects milder adult/odonto presentations.
Molecular diagnosis allows predictive testing, confirming a diagnostic role and guiding
disease management planning for genetic counseling.
Diagnosis
Based upon clinical, radiological and biochemical characteristics:
- Low serum alkaline phosphatase levels confirm through enzymatic assay.
- Increased urinary PPi and Pi ratios evidence impaired hydrolysis.
- Severe hypomineralization observed on plain films/DEXA scanning.
- Genetic testing establishes causality identifying ALPL variants.
A high index of suspicion guides tissue biopsy/enzyme histochemistry or genetic analysis
establishing HPP diagnosis through correlated evidence of deficiency.
Disease Management
Supportive care addresses morbidity utilizing multidisciplinary teams:
- Anticonvulsants manage epilepsy. Anti-rickets vitamin/mineral supplementation.
- Bisphosphonates, parathyroid hormone use show variable efficacy.
- Surgical intervention addresses pseudofractures/craniosynostosis.
- Orthopedic bracing, mobility aids address fractures/deformities.
- Dental care extracts affected teeth, braces retainers for those at risk.
- Enzyme replacement therapies recently approved demonstrate efficacy improving skeletal
health and stabilizing disease course.
- Bone marrow/liver transplant explored but enzymatic supplementation preferred.
- Palliative symptom control addresses bone pain/mobility impairment quality of life.
Future Directions
Research aims improving quality of life through management refinements:
- Clarifying genotype-phenotype relationships guiding prognostication and early intervention
timing.
- Assessment of long-term enzyme replacement therapy outcomes and monitoring.
- Developmental biomarker identification enables newborn screening program
implementation.
- Gene/cellular therapies deliver TNSALP more broadly throughout skeletal tissues.
- Disease modeling explores modifying secondary pathways contributing to
hypomineralization for adjunct targeting.
Overall, continued efforts optimizing HPP recognition and precision care centered on
mechanistic understanding promise mitigating morbidity from this treatable orphan bone
disease.
Hypophosphatasia (HPP) represents an inherited metabolic bone disease characterized by
defective mineralization of bone and teeth due to low levels of tissue-nonspecific alkaline
phosphatase (TNSALP). The condition arises from loss-of-function variants in the ALPL
gene encoding TNSALP, disrupting bone matrix mineralization through impaired
pyrophosphate hydrolysis. Clinical presentations range from perinatal to adult-onset forms
dependent on residual enzymatic activity and involvement of extraskeletal sites like the liver,
kidney, and lungs.
This review summarizes TNSALP biology regulating skeletal mineralization, the spectrum of
HPP clinical phenotypes linked to ALPL genotype, diagnostic testing through biochemical
and genetic confirmation, and emerging enzyme replacement therapies recently approved
showing efficacy addressing skeletal manifestations and complications. By understanding
how disrupted ALPL signaling impacts skeletal mineralization, continued research promises
further delineating genotype-phenotype correlations and optimizing management alleviating
disease burden through individualized precision approaches.
Physiological Role of TNSALP
TNSALP dephosphorylates inorganic pyrophosphate (PPi), an inhibitor of hydroxyapatite
crystal growth that regulates mineralization:
- Produced by osteoblasts/chrondrocytes, TNSALP anchors cell surfaces through a
glycosylphosphatidylinositol linkage.
- Hydrolyzing PPi favors hydroxyapatite mineral deposition within newly formed bone
osteoid and growth plate cartilage.
- Other substrates include phosphoethanolamine involved in lipid metabolism.
- Ubiquitously expressed, with predominant skeletal localization and liver/kidney
involvement in certain perinatal HPP presentations.
Deficient TNSALP activity elevates PPi, impairing skeletal mineralization through reduced
hydroxyapatite nucleation/crystal growth leading to hypomineralization manifestations across
developmental and aging bones.
Clinical Features of HPP
Presentations depend on residual TNSALP activity levels:
- Perinatal (lethal) - Undermineralized bones, fractures, respiratory failure.
- Perinatal benign - Shortened long bones, fractures, defective teeth.
- Infantile - Wormian bones, craniosynostosis, seizures due to rickets.
- Childhood/adult - Fractures, back pain, premature loss of teeth.
- Odonto - Dental abnormalities involving premature tooth loss.
- Benign - Rare, asymptomatic mild elevations in bone/liver enzymes.
Additional complications like renal calcifications/failure possibly impact liver and heart
valvular function in subset. Phenotypes show intrafamilial variability.
Genetics of HPP
All arise from biallelic loss of function mutations in ALPL encoding the TNSALP
phosphatase:
- Over 300 ALPL variants span missense, nonsense, splicing defects impacting
activity/stability.
- Variable expressivity depends on residual enzymatic activity from mutations conferring
partial versus complete loss of function.
- Homozygosity associated with severe perinatal phenotypes while heterozygosity often
reflects milder adult/odonto presentations.
Molecular diagnosis allows predictive testing, confirming a diagnostic role and guiding
disease management planning for genetic counseling.
Diagnosis
Based upon clinical, radiological and biochemical characteristics:
- Low serum alkaline phosphatase levels confirm through enzymatic assay.
- Increased urinary PPi and Pi ratios evidence impaired hydrolysis.
- Severe hypomineralization observed on plain films/DEXA scanning.
- Genetic testing establishes causality identifying ALPL variants.
A high index of suspicion guides tissue biopsy/enzyme histochemistry or genetic analysis
establishing HPP diagnosis through correlated evidence of deficiency.
Disease Management
Supportive care addresses morbidity utilizing multidisciplinary teams:
- Anticonvulsants manage epilepsy. Anti-rickets vitamin/mineral supplementation.
- Bisphosphonates, parathyroid hormone use show variable efficacy.
- Surgical intervention addresses pseudofractures/craniosynostosis.
- Orthopedic bracing, mobility aids address fractures/deformities.
- Dental care extracts affected teeth, braces retainers for those at risk.
- Enzyme replacement therapies recently approved demonstrate efficacy improving skeletal
health and stabilizing disease course.
- Bone marrow/liver transplant explored but enzymatic supplementation preferred.
- Palliative symptom control addresses bone pain/mobility impairment quality of life.
Future Directions
Research aims improving quality of life through management refinements:
- Clarifying genotype-phenotype relationships guiding prognostication and early intervention
timing.
- Assessment of long-term enzyme replacement therapy outcomes and monitoring.
- Developmental biomarker identification enables newborn screening program
implementation.
- Gene/cellular therapies deliver TNSALP more broadly throughout skeletal tissues.
- Disease modeling explores modifying secondary pathways contributing to
hypomineralization for adjunct targeting.
Overall, continued efforts optimizing HPP recognition and precision care centered on
mechanistic understanding promise mitigating morbidity from this treatable orphan bone
disease.
Hypophosphatasia (HPP) represents an inherited metabolic bone disease characterized by
defective mineralization of bone and teeth due to low levels of tissue-nonspecific alkaline
phosphatase (TNSALP). The condition arises from loss-of-function variants in the ALPL
gene encoding TNSALP, disrupting bone matrix mineralization through impaired
pyrophosphate hydrolysis. Clinical presentations range from perinatal to adult-onset forms
dependent on residual enzymatic activity and involvement of extraskeletal sites like the liver,
kidney, and lungs.
This review summarizes TNSALP biology regulating skeletal mineralization, the spectrum of
HPP clinical phenotypes linked to ALPL genotype, diagnostic testing through biochemical
and genetic confirmation, and emerging enzyme replacement therapies recently approved
showing efficacy addressing skeletal manifestations and complications. By understanding
how disrupted ALPL signaling impacts skeletal mineralization, continued research promises
further delineating genotype-phenotype correlations and optimizing management alleviating
disease burden through individualized precision approaches.
Physiological Role of TNSALP
TNSALP dephosphorylates inorganic pyrophosphate (PPi), an inhibitor of hydroxyapatite
crystal growth that regulates mineralization:
- Produced by osteoblasts/chrondrocytes, TNSALP anchors cell surfaces through a
glycosylphosphatidylinositol linkage.
- Hydrolyzing PPi favors hydroxyapatite mineral deposition within newly formed bone
osteoid and growth plate cartilage.
- Other substrates include phosphoethanolamine involved in lipid metabolism.
- Ubiquitously expressed, with predominant skeletal localization and liver/kidney
involvement in certain perinatal HPP presentations.
Deficient TNSALP activity elevates PPi, impairing skeletal mineralization through reduced
hydroxyapatite nucleation/crystal growth leading to hypomineralization manifestations across
developmental and aging bones.
Clinical Features of HPP
Presentations depend on residual TNSALP activity levels:
- Perinatal (lethal) - Undermineralized bones, fractures, respiratory failure.
- Perinatal benign - Shortened long bones, fractures, defective teeth.
- Infantile - Wormian bones, craniosynostosis, seizures due to rickets.
- Childhood/adult - Fractures, back pain, premature loss of teeth.
- Odonto - Dental abnormalities involving premature tooth loss.
- Benign - Rare, asymptomatic mild elevations in bone/liver enzymes.
Additional complications like renal calcifications/failure possibly impact liver and heart
valvular function in subset. Phenotypes show intrafamilial variability.
Genetics of HPP
All arise from biallelic loss of function mutations in ALPL encoding the TNSALP
phosphatase:
- Over 300 ALPL variants span missense, nonsense, splicing defects impacting
activity/stability.
- Variable expressivity depends on residual enzymatic activity from mutations conferring
partial versus complete loss of function.
- Homozygosity associated with severe perinatal phenotypes while heterozygosity often
reflects milder adult/odonto presentations.
Molecular diagnosis allows predictive testing, confirming a diagnostic role and guiding
disease management planning for genetic counseling.
Diagnosis
Based upon clinical, radiological and biochemical characteristics:
- Low serum alkaline phosphatase levels confirm through enzymatic assay.
- Increased urinary PPi and Pi ratios evidence impaired hydrolysis.
- Severe hypomineralization observed on plain films/DEXA scanning.
- Genetic testing establishes causality identifying ALPL variants.
A high index of suspicion guides tissue biopsy/enzyme histochemistry or genetic analysis
establishing HPP diagnosis through correlated evidence of deficiency.
Disease Management
Supportive care addresses morbidity utilizing multidisciplinary teams:
- Anticonvulsants manage epilepsy. Anti-rickets vitamin/mineral supplementation.
- Bisphosphonates, parathyroid hormone use show variable efficacy.
- Surgical intervention addresses pseudofractures/craniosynostosis.
- Orthopedic bracing, mobility aids address fractures/deformities.
- Dental care extracts affected teeth, braces retainers for those at risk.
- Enzyme replacement therapies recently approved demonstrate efficacy improving skeletal
health and stabilizing disease course.
- Bone marrow/liver transplant explored but enzymatic supplementation preferred.
- Palliative symptom control addresses bone pain/mobility impairment quality of life.
Future Directions
Research aims improving quality of life through management refinements:
- Clarifying genotype-phenotype relationships guiding prognostication and early intervention
timing.
- Assessment of long-term enzyme replacement therapy outcomes and monitoring.
- Developmental biomarker identification enables newborn screening program
implementation.
- Gene/cellular therapies deliver TNSALP more broadly throughout skeletal tissues.
- Disease modeling explores modifying secondary pathways contributing to
hypomineralization for adjunct targeting.
Overall, continued efforts optimizing HPP recognition and precision care centered on
mechanistic understanding promise mitigating morbidity from this treatable orphan bone
disease.
Hypophosphatasia (HPP) represents an inherited metabolic bone disease characterized by
defective mineralization of bone and teeth due to low levels of tissue-nonspecific alkaline
phosphatase (TNSALP). The condition arises from loss-of-function variants in the ALPL
gene encoding TNSALP, disrupting bone matrix mineralization through impaired
pyrophosphate hydrolysis. Clinical presentations range from perinatal to adult-onset forms
dependent on residual enzymatic activity and involvement of extraskeletal sites like the liver,
kidney, and lungs.
This review summarizes TNSALP biology regulating skeletal mineralization, the spectrum of
HPP clinical phenotypes linked to ALPL genotype, diagnostic testing through biochemical
and genetic confirmation, and emerging enzyme replacement therapies recently approved
showing efficacy addressing skeletal manifestations and complications. By understanding
how disrupted ALPL signaling impacts skeletal mineralization, continued research promises
further delineating genotype-phenotype correlations and optimizing management alleviating
disease burden through individualized precision approaches.
Physiological Role of TNSALP
TNSALP dephosphorylates inorganic pyrophosphate (PPi), an inhibitor of hydroxyapatite
crystal growth that regulates mineralization:
- Produced by osteoblasts/chrondrocytes, TNSALP anchors cell surfaces through a
glycosylphosphatidylinositol linkage.
- Hydrolyzing PPi favors hydroxyapatite mineral deposition within newly formed bone
osteoid and growth plate cartilage.
- Other substrates include phosphoethanolamine involved in lipid metabolism.
- Ubiquitously expressed, with predominant skeletal localization and liver/kidney
involvement in certain perinatal HPP presentations.
Deficient TNSALP activity elevates PPi, impairing skeletal mineralization through reduced
hydroxyapatite nucleation/crystal growth leading to hypomineralization manifestations across
developmental and aging bones.
Clinical Features of HPP
Presentations depend on residual TNSALP activity levels:
- Perinatal (lethal) - Undermineralized bones, fractures, respiratory failure.
- Perinatal benign - Shortened long bones, fractures, defective teeth.
- Infantile - Wormian bones, craniosynostosis, seizures due to rickets.
- Childhood/adult - Fractures, back pain, premature loss of teeth.
- Odonto - Dental abnormalities involving premature tooth loss.
- Benign - Rare, asymptomatic mild elevations in bone/liver enzymes.
Additional complications like renal calcifications/failure possibly impact liver and heart
valvular function in subset. Phenotypes show intrafamilial variability.
Genetics of HPP
All arise from biallelic loss of function mutations in ALPL encoding the TNSALP
phosphatase:
- Over 300 ALPL variants span missense, nonsense, splicing defects impacting
activity/stability.
- Variable expressivity depends on residual enzymatic activity from mutations conferring
partial versus complete loss of function.
- Homozygosity associated with severe perinatal phenotypes while heterozygosity often
reflects milder adult/odonto presentations.
Molecular diagnosis allows predictive testing, confirming a diagnostic role and guiding
disease management planning for genetic counseling.
Diagnosis
Based upon clinical, radiological and biochemical characteristics:
- Low serum alkaline phosphatase levels confirm through enzymatic assay.
- Increased urinary PPi and Pi ratios evidence impaired hydrolysis.
- Severe hypomineralization observed on plain films/DEXA scanning.
- Genetic testing establishes causality identifying ALPL variants.
A high index of suspicion guides tissue biopsy/enzyme histochemistry or genetic analysis
establishing HPP diagnosis through correlated evidence of deficiency.
Disease Management
Supportive care addresses morbidity utilizing multidisciplinary teams:
- Anticonvulsants manage epilepsy. Anti-rickets vitamin/mineral supplementation.
- Bisphosphonates, parathyroid hormone use show variable efficacy.
- Surgical intervention addresses pseudofractures/craniosynostosis.
- Orthopedic bracing, mobility aids address fractures/deformities.
- Dental care extracts affected teeth, braces retainers for those at risk.
- Enzyme replacement therapies recently approved demonstrate efficacy improving skeletal
health and stabilizing disease course.
- Bone marrow/liver transplant explored but enzymatic supplementation preferred.
- Palliative symptom control addresses bone pain/mobility impairment quality of life.
Future Directions
Research aims improving quality of life through management refinements:
- Clarifying genotype-phenotype relationships guiding prognostication and early intervention
timing.
- Assessment of long-term enzyme replacement therapy outcomes and monitoring.
- Developmental biomarker identification enables newborn screening program
implementation.
- Gene/cellular therapies deliver TNSALP more broadly throughout skeletal tissues.
- Disease modeling explores modifying secondary pathways contributing to
hypomineralization for adjunct targeting.
Overall, continued efforts optimizing HPP recognition and precision care centered on
mechanistic understanding promise mitigating morbidity from this treatable orphan bone
disease.
Hypophosphatasia (HPP) represents an inherited metabolic bone disease characterized by
defective mineralization of bone and teeth due to low levels of tissue-nonspecific alkaline
phosphatase (TNSALP). The condition arises from loss-of-function variants in the ALPL
gene encoding TNSALP, disrupting bone matrix mineralization through impaired
pyrophosphate hydrolysis. Clinical presentations range from perinatal to adult-onset forms
dependent on residual enzymatic activity and involvement of extraskeletal sites like the liver,
kidney, and lungs.
This review summarizes TNSALP biology regulating skeletal mineralization, the spectrum of
HPP clinical phenotypes linked to ALPL genotype, diagnostic testing through biochemical
and genetic confirmation, and emerging enzyme replacement therapies recently approved
showing efficacy addressing skeletal manifestations and complications. By understanding
how disrupted ALPL signaling impacts skeletal mineralization, continued research promises
further delineating genotype-phenotype correlations and optimizing management alleviating
disease burden through individualized precision approaches.
Physiological Role of TNSALP
TNSALP dephosphorylates inorganic pyrophosphate (PPi), an inhibitor of hydroxyapatite
crystal growth that regulates mineralization:
- Produced by osteoblasts/chrondrocytes, TNSALP anchors cell surfaces through a
glycosylphosphatidylinositol linkage.
- Hydrolyzing PPi favors hydroxyapatite mineral deposition within newly formed bone
osteoid and growth plate cartilage.
- Other substrates include phosphoethanolamine involved in lipid metabolism.
- Ubiquitously expressed, with predominant skeletal localization and liver/kidney
involvement in certain perinatal HPP presentations.
Deficient TNSALP activity elevates PPi, impairing skeletal mineralization through reduced
hydroxyapatite nucleation/crystal growth leading to hypomineralization manifestations across
developmental and aging bones.
Clinical Features of HPP
Presentations depend on residual TNSALP activity levels:
- Perinatal (lethal) - Undermineralized bones, fractures, respiratory failure.
- Perinatal benign - Shortened long bones, fractures, defective teeth.
- Infantile - Wormian bones, craniosynostosis, seizures due to rickets.
- Childhood/adult - Fractures, back pain, premature loss of teeth.
- Odonto - Dental abnormalities involving premature tooth loss.
- Benign - Rare, asymptomatic mild elevations in bone/liver enzymes.
Additional complications like renal calcifications/failure possibly impact liver and heart
valvular function in subset. Phenotypes show intrafamilial variability.
Genetics of HPP
All arise from biallelic loss of function mutations in ALPL encoding the TNSALP
phosphatase:
- Over 300 ALPL variants span missense, nonsense, splicing defects impacting
activity/stability.
- Variable expressivity depends on residual enzymatic activity from mutations conferring
partial versus complete loss of function.
- Homozygosity associated with severe perinatal phenotypes while heterozygosity often
reflects milder adult/odonto presentations.
Molecular diagnosis allows predictive testing, confirming a diagnostic role and guiding
disease management planning for genetic counseling.
Diagnosis
Based upon clinical, radiological and biochemical characteristics:
- Low serum alkaline phosphatase levels confirm through enzymatic assay.
- Increased urinary PPi and Pi ratios evidence impaired hydrolysis.
- Severe hypomineralization observed on plain films/DEXA scanning.
- Genetic testing establishes causality identifying ALPL variants.
A high index of suspicion guides tissue biopsy/enzyme histochemistry or genetic analysis
establishing HPP diagnosis through correlated evidence of deficiency.
Disease Management
Supportive care addresses morbidity utilizing multidisciplinary teams:
- Anticonvulsants manage epilepsy. Anti-rickets vitamin/mineral supplementation.
- Bisphosphonates, parathyroid hormone use show variable efficacy.
- Surgical intervention addresses pseudofractures/craniosynostosis.
- Orthopedic bracing, mobility aids address fractures/deformities.
- Dental care extracts affected teeth, braces retainers for those at risk.
- Enzyme replacement therapies recently approved demonstrate efficacy improving skeletal
health and stabilizing disease course.
- Bone marrow/liver transplant explored but enzymatic supplementation preferred.
- Palliative symptom control addresses bone pain/mobility impairment quality of life.
Future Directions
Research aims improving quality of life through management refinements:
- Clarifying genotype-phenotype relationships guiding prognostication and early intervention
timing.
- Assessment of long-term enzyme replacement therapy outcomes and monitoring.
- Developmental biomarker identification enables newborn screening program
implementation.
- Gene/cellular therapies deliver TNSALP more broadly throughout skeletal tissues.
- Disease modeling explores modifying secondary pathways contributing to
hypomineralization for adjunct targeting.
Overall, continued efforts optimizing HPP recognition and precision care centered on
mechanistic understanding promise mitigating morbidity from this treatable orphan bone
disease.
Hypophosphatasia (HPP) represents an inherited metabolic bone disease characterized by
defective mineralization of bone and teeth due to low levels of tissue-nonspecific alkaline
phosphatase (TNSALP). The condition arises from loss-of-function variants in the ALPL
gene encoding TNSALP, disrupting bone matrix mineralization through impaired
pyrophosphate hydrolysis. Clinical presentations range from perinatal to adult-onset forms
dependent on residual enzymatic activity and involvement of extraskeletal sites like the liver,
kidney, and lungs.
This review summarizes TNSALP biology regulating skeletal mineralization, the spectrum of
HPP clinical phenotypes linked to ALPL genotype, diagnostic testing through biochemical
and genetic confirmation, and emerging enzyme replacement therapies recently approved
showing efficacy addressing skeletal manifestations and complications. By understanding
how disrupted ALPL signaling impacts skeletal mineralization, continued research promises
further delineating genotype-phenotype correlations and optimizing management alleviating
disease burden through individualized precision approaches.
Physiological Role of TNSALP
TNSALP dephosphorylates inorganic pyrophosphate (PPi), an inhibitor of hydroxyapatite
crystal growth that regulates mineralization:
- Produced by osteoblasts/chrondrocytes, TNSALP anchors cell surfaces through a
glycosylphosphatidylinositol linkage.
- Hydrolyzing PPi favors hydroxyapatite mineral deposition within newly formed bone
osteoid and growth plate cartilage.
- Other substrates include phosphoethanolamine involved in lipid metabolism.
- Ubiquitously expressed, with predominant skeletal localization and liver/kidney
involvement in certain perinatal HPP presentations.
Deficient TNSALP activity elevates PPi, impairing skeletal mineralization through reduced
hydroxyapatite nucleation/crystal growth leading to hypomineralization manifestations across
developmental and aging bones.
Clinical Features of HPP
Presentations depend on residual TNSALP activity levels:
- Perinatal (lethal) - Undermineralized bones, fractures, respiratory failure.
- Perinatal benign - Shortened long bones, fractures, defective teeth.
- Infantile - Wormian bones, craniosynostosis, seizures due to rickets.
- Childhood/adult - Fractures, back pain, premature loss of teeth.
- Odonto - Dental abnormalities involving premature tooth loss.
- Benign - Rare, asymptomatic mild elevations in bone/liver enzymes.
Additional complications like renal calcifications/failure possibly impact liver and heart
valvular function in subset. Phenotypes show intrafamilial variability.
Genetics of HPP
All arise from biallelic loss of function mutations in ALPL encoding the TNSALP
phosphatase:
- Over 300 ALPL variants span missense, nonsense, splicing defects impacting
activity/stability.
- Variable expressivity depends on residual enzymatic activity from mutations conferring
partial versus complete loss of function.
- Homozygosity associated with severe perinatal phenotypes while heterozygosity often
reflects milder adult/odonto presentations.
Molecular diagnosis allows predictive testing, confirming a diagnostic role and guiding
disease management planning for genetic counseling.
Diagnosis
Based upon clinical, radiological and biochemical characteristics:
- Low serum alkaline phosphatase levels confirm through enzymatic assay.
- Increased urinary PPi and Pi ratios evidence impaired hydrolysis.
- Severe hypomineralization observed on plain films/DEXA scanning.
- Genetic testing establishes causality identifying ALPL variants.
A high index of suspicion guides tissue biopsy/enzyme histochemistry or genetic analysis
establishing HPP diagnosis through correlated evidence of deficiency.
Disease Management
Supportive care addresses morbidity utilizing multidisciplinary teams:
- Anticonvulsants manage epilepsy. Anti-rickets vitamin/mineral supplementation.
- Bisphosphonates, parathyroid hormone use show variable efficacy.
- Surgical intervention addresses pseudofractures/craniosynostosis.
- Orthopedic bracing, mobility aids address fractures/deformities.
- Dental care extracts affected teeth, braces retainers for those at risk.
- Enzyme replacement therapies recently approved demonstrate efficacy improving skeletal
health and stabilizing disease course.
- Bone marrow/liver transplant explored but enzymatic supplementation preferred.
- Palliative symptom control addresses bone pain/mobility impairment quality of life.
Future Directions
Research aims improving quality of life through management refinements:
- Clarifying genotype-phenotype relationships guiding prognostication and early intervention
timing.
- Assessment of long-term enzyme replacement therapy outcomes and monitoring.
- Developmental biomarker identification enables newborn screening program
implementation.
- Gene/cellular therapies deliver TNSALP more broadly throughout skeletal tissues.
- Disease modeling explores modifying secondary pathways contributing to
hypomineralization for adjunct targeting.
Overall, continued efforts optimizing HPP recognition and precision care centered on
mechanistic understanding promise mitigating morbidity from this treatable orphan bone
disease.
Hypophosphatasia (HPP) represents an inherited metabolic bone disease characterized by
defective mineralization of bone and teeth due to low levels of tissue-nonspecific alkaline
phosphatase (TNSALP). The condition arises from loss-of-function variants in the ALPL
gene encoding TNSALP, disrupting bone matrix mineralization through impaired
pyrophosphate hydrolysis. Clinical presentations range from perinatal to adult-onset forms
dependent on residual enzymatic activity and involvement of extraskeletal sites like the liver,
kidney, and lungs.
This review summarizes TNSALP biology regulating skeletal mineralization, the spectrum of
HPP clinical phenotypes linked to ALPL genotype, diagnostic testing through biochemical
and genetic confirmation, and emerging enzyme replacement therapies recently approved
showing efficacy addressing skeletal manifestations and complications. By understanding
how disrupted ALPL signaling impacts skeletal mineralization, continued research promises
further delineating genotype-phenotype correlations and optimizing management alleviating
disease burden through individualized precision approaches.
Physiological Role of TNSALP
TNSALP dephosphorylates inorganic pyrophosphate (PPi), an inhibitor of hydroxyapatite
crystal growth that regulates mineralization:
- Produced by osteoblasts/chrondrocytes, TNSALP anchors cell surfaces through a
glycosylphosphatidylinositol linkage.
- Hydrolyzing PPi favors hydroxyapatite mineral deposition within newly formed bone
osteoid and growth plate cartilage.
- Other substrates include phosphoethanolamine involved in lipid metabolism.
- Ubiquitously expressed, with predominant skeletal localization and liver/kidney
involvement in certain perinatal HPP presentations.
Deficient TNSALP activity elevates PPi, impairing skeletal mineralization through reduced
hydroxyapatite nucleation/crystal growth leading to hypomineralization manifestations across
developmental and aging bones.
Clinical Features of HPP
Presentations depend on residual TNSALP activity levels:
- Perinatal (lethal) - Undermineralized bones, fractures, respiratory failure.
- Perinatal benign - Shortened long bones, fractures, defective teeth.
- Infantile - Wormian bones, craniosynostosis, seizures due to rickets.
- Childhood/adult - Fractures, back pain, premature loss of teeth.
- Odonto - Dental abnormalities involving premature tooth loss.
- Benign - Rare, asymptomatic mild elevations in bone/liver enzymes.
Additional complications like renal calcifications/failure possibly impact liver and heart
valvular function in subset. Phenotypes show intrafamilial variability.
Genetics of HPP
All arise from biallelic loss of function mutations in ALPL encoding the TNSALP
phosphatase:
- Over 300 ALPL variants span missense, nonsense, splicing defects impacting
activity/stability.
- Variable expressivity depends on residual enzymatic activity from mutations conferring
partial versus complete loss of function.
- Homozygosity associated with severe perinatal phenotypes while heterozygosity often
reflects milder adult/odonto presentations.
Molecular diagnosis allows predictive testing, confirming a diagnostic role and guiding
disease management planning for genetic counseling.
Diagnosis
Based upon clinical, radiological and biochemical characteristics:
- Low serum alkaline phosphatase levels confirm through enzymatic assay.
- Increased urinary PPi and Pi ratios evidence impaired hydrolysis.
- Severe hypomineralization observed on plain films/DEXA scanning.
- Genetic testing establishes causality identifying ALPL variants.
A high index of suspicion guides tissue biopsy/enzyme histochemistry or genetic analysis
establishing HPP diagnosis through correlated evidence of deficiency.
Disease Management
Supportive care addresses morbidity utilizing multidisciplinary teams:
- Anticonvulsants manage epilepsy. Anti-rickets vitamin/mineral supplementation.
- Bisphosphonates, parathyroid hormone use show variable efficacy.
- Surgical intervention addresses pseudofractures/craniosynostosis.
- Orthopedic bracing, mobility aids address fractures/deformities.
- Dental care extracts affected teeth, braces retainers for those at risk.
- Enzyme replacement therapies recently approved demonstrate efficacy improving skeletal
health and stabilizing disease course.
- Bone marrow/liver transplant explored but enzymatic supplementation preferred.
- Palliative symptom control addresses bone pain/mobility impairment quality of life.
Future Directions
Research aims improving quality of life through management refinements:
- Clarifying genotype-phenotype relationships guiding prognostication and early intervention
timing.
- Assessment of long-term enzyme replacement therapy outcomes and monitoring.
- Developmental biomarker identification enables newborn screening program
implementation.
- Gene/cellular therapies deliver TNSALP more broadly throughout skeletal tissues.
- Disease modeling explores modifying secondary pathways contributing to
hypomineralization for adjunct targeting.
Overall, continued efforts optimizing HPP recognition and precision care centered on
mechanistic understanding promise mitigating morbidity from this treatable orphan bone
disease.
